Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 1.718
Filtrer
1.
Photodermatol Photoimmunol Photomed ; 40(4): e12985, 2024 Jul.
Article de Anglais | MEDLINE | ID: mdl-38845468

RÉSUMÉ

BACKGROUND: Photoprotection is the first measure in the prevention and treatment of the deleterious effects that sunlight can cause on the skin. It is well known that prolonged exposure to solar radiation leads to acute and chronic complications, such as erythema, accelerated skin aging, proinflammatory and procarcinogenic effects, and eye damage, among others. METHODS: A better understanding of the molecules that can protect against ultraviolet radiation and their effects will lead to improvements in skin health. RESULTS: Most of these effects of the sunlight are modulated by oxidative stress and proinflammatory mechanisms, therefore, the supplementation of substances that can regulate and neutralize reactive oxygen species would be beneficial for skin protection. Current evidence indicates that systemic photoprotection should be used as an adjunctive measure to topical photoprotection. CONCLUSION: Oral photoprotectors are a promising option in improving protection against damage induced by UVR, as they contain active ingredients that increase the antioxidant effects of the body, complementing other photoprotection measures. We present a review of oral photoprotectors and their effects.


Sujet(s)
Agents protecteurs , Rayons ultraviolets , Humains , Administration par voie orale , Antioxydants/administration et posologie , Stress oxydatif/effets des médicaments et des substances chimiques , Espèces réactives de l'oxygène/métabolisme , Peau/métabolisme , Peau/effets des radiations , Peau/effets des médicaments et des substances chimiques , Lumière du soleil/effets indésirables , Rayons ultraviolets/effets indésirables , Agents protecteurs/administration et posologie
2.
Zhongguo Zhong Yao Za Zhi ; 49(8): 2188-2196, 2024 Apr.
Article de Chinois | MEDLINE | ID: mdl-38812234

RÉSUMÉ

This study aims to investigate the protective effect of salidroside(SAL) on renal damage in diabetic nephropathy(DN) mice based on the receptor for advanced glycation end products/janus activated kinase 1/signal transduction and activator of transcription 3(RAGE/JAK1/STAT3) signaling pathway. The mouse DN model was established by high-fat/high-sucrose diets combined with intraperitoneal injection of streptozocin(STZ). Mice were randomly divided into normal group, model group, low-dose SAL group(20 mg·kg~(-1)), high-dose SAL group(100 mg·kg~(-1)), and metformin group(140 mg·kg~(-1)), with 12 mice in each group. After establishing the DN model, mice were given drugs or solvent intragastrically, once a day for consecutive 10 weeks. Body weight, daily water intake, and fasting blood glucose(FBG) were measured every two weeks. After the last dose, the glucose tolerance test was performed, and the samples of 24-hour urine, serum, and kidney tissue were collected. The levels of 24 hours urinary total protein(24 h-UTP), serum creatinine(Scr), blood urea nitrogen(BUN), triglyceride(TG), total cholesterol(TC), low density lipoprotein cholesterol(LDL-C), and high density lipoprotein cholesterol(HDL-C) were detected by biochemical tests. Periodic acid-schiff(PAS) staining was used to observe the pathological changes in the kidney tissue. The protein expressions of α-smooth muscle actin(α-SMA), vimentin, and advanced glycation end products(AGEs) in kidneys were detected by immunohistochemical staining. The activities of superoxide dismutase(SOD), catalase(CAT), glutathione peroxidase(GSH-PX), and the level of malondialdehyde(MDA) in kidneys were detected by using a corresponding detection kit. Enzyme-linked immunosorbent assay(ELISA) was used to detect the levels of AGEs, carboxymethyllysine(CML), and carboxyethyllysine(CEL) in serum. The protein expressions of RAGE and the phosphorylation level of JAK1 and STAT3 in kidneys were detected by Western blot. Compared with the normal group, the levels of FBG, the area under the curve of glucose(AUCG), water intake, kidney index, 24 h-UTP, tubular injury score, extracellular matrix deposition ratio of the renal glomerulus, the serum levels of Scr, BUN, TG, LDL-C, AGEs, CEL, and CML, the level of MDA, the protein expressions of α-SMA, vimentin, AGEs, and RAGE, and the phosphorylation level of JAK1 and STAT3 in kidney tissue were increased significantly(P<0.01), while the level of HDL-C in serum and the activity of SOD, CAT, and GSH-PX in kidney tissue were decreased significantly(P<0.01). Compared with the model group, the above indexes of the high-dose SAL group were reversed significantly(P<0.05 or P<0.01). In conclusion, this study suggests that SAL can alleviate oxidative stress and renal fibrosis by inhibiting the activation of AGEs-mediated RAGE/JAK1/STAT3 signaling axis, thus playing a potential role in the treatment of DN.


Sujet(s)
Néphropathies diabétiques , Glucosides , Janus kinase 1 , Rein , Phénols , Récepteur spécifique des produits finaux de glycosylation avancée , Facteur de transcription STAT-3 , Transduction du signal , Animaux , Souris , Néphropathies diabétiques/traitement médicamenteux , Néphropathies diabétiques/métabolisme , Glucosides/pharmacologie , Glucosides/administration et posologie , Récepteur spécifique des produits finaux de glycosylation avancée/métabolisme , Récepteur spécifique des produits finaux de glycosylation avancée/génétique , Transduction du signal/effets des médicaments et des substances chimiques , Mâle , Rein/effets des médicaments et des substances chimiques , Rein/métabolisme , Rein/anatomopathologie , Phénols/pharmacologie , Janus kinase 1/métabolisme , Janus kinase 1/génétique , Facteur de transcription STAT-3/métabolisme , Facteur de transcription STAT-3/génétique , Agents protecteurs/pharmacologie , Agents protecteurs/administration et posologie , Humains , Souris de lignée C57BL , Glycémie/métabolisme , Glycémie/effets des médicaments et des substances chimiques
3.
J Agric Food Chem ; 72(26): 14956-14966, 2024 Jul 03.
Article de Anglais | MEDLINE | ID: mdl-38820047

RÉSUMÉ

Atrazine (ATR) is a widely used herbicide worldwide that can cause kidney damage in humans and animals by accumulation in water and soil. Lycopene (LYC), a carotenoid with numerous biological activities, plays an important role in kidney protection due to its potent antioxidant and anti-inflammatory effects. The current study sought to investigate the role of interactions between mtDNA and the cGAS-STING signaling pathway in LYC mitigating PANoptosis and inflammation in kidneys induced by ATR exposure. In our research, 350 mice were orally administered LYC (5 mg/kg BW/day) and ATR (50 or 200 mg/kg BW/day) for 21 days. Our results reveal that ATR exposure induces a decrease in mtDNA stability, resulting in the release of mtDNA into the cytoplasm through the mPTP pore and the BAX pore and the mobilization of the cGAS-STING pathway, thereby inducing renal PANoptosis and inflammation. LYC can inhibit the above changes caused by ATR. In conclusion, LYC inhibited ATR exposure-induced histopathological changes, renal PANoptosis, and inflammation by inhibiting the cGAS-STING pathway. Our results demonstrate the positive role of LYC in ATR-induced renal injury and provide a new therapeutic target for treating renal diseases in the clinic.


Sujet(s)
Atrazine , ADN mitochondrial , Rein , Lycopène , Protéines membranaires , Agents protecteurs , Animaux , Souris , Atrazine/toxicité , Rein/effets des médicaments et des substances chimiques , Rein/métabolisme , Protéines membranaires/génétique , Protéines membranaires/métabolisme , Lycopène/pharmacologie , Lycopène/administration et posologie , ADN mitochondrial/génétique , ADN mitochondrial/métabolisme , Mâle , Agents protecteurs/pharmacologie , Agents protecteurs/administration et posologie , Humains , Herbicides , Maladies du rein/métabolisme , Maladies du rein/induit chimiquement , Maladies du rein/prévention et contrôle , Maladies du rein/génétique , Maladies du rein/traitement médicamenteux , Nucleotidyltransferases/génétique , Nucleotidyltransferases/métabolisme , Transduction du signal/effets des médicaments et des substances chimiques
4.
J Agric Food Chem ; 72(20): 11515-11530, 2024 May 22.
Article de Anglais | MEDLINE | ID: mdl-38726599

RÉSUMÉ

Chronic stress is a major inducer of anxiety and insomnia. Milk casein has been studied for its stress-relieving effects. We previously prepared a casein hydrolysate (CP) rich in the sleep-enhancing peptide YPVEPF, and this study aims to systemically investigate the different protective effects of CP and casein on dysfunction and anxiety/insomnia behavior and its underlying mechanisms in chronically stressed mice. Behavioral results showed that CP ameliorated stress-induced insomnia and anxiety more effectively than milk casein, and this difference in amelioration was highly correlated with an increase in GABA, 5-HT, GABAA, 5-HT1A receptors, and BDNF and a decrease in IL-6 and NMDA receptors in stressed mice. Furthermore, CP restored these dysfunctions in the brain and colon by activating the HPA response, modulating the ERK/CREB-BDNF-TrκB signaling pathway, and alleviating inflammation. The abundant YPVEPF (1.20 ± 0.04%) and Tyr-based/Trp-containing peptides of CP may be the key reasons for its different effects compared to casein. Thus, this work revealed the main active structures of CP and provided a novel dietary intervention strategy for the prevention and treatment of chronic-stress-induced dysfunction and anxiety/insomnia behaviors.


Sujet(s)
Anxiété , Encéphale , Caséines , Troubles de l'endormissement et du maintien du sommeil , Animaux , Mâle , Souris , Anxiété/prévention et contrôle , Comportement animal/effets des médicaments et des substances chimiques , Encéphale/métabolisme , Encéphale/effets des médicaments et des substances chimiques , Facteur neurotrophique dérivé du cerveau/métabolisme , Facteur neurotrophique dérivé du cerveau/génétique , Caséines/composition chimique , Caséines/administration et posologie , Agents protecteurs/administration et posologie , Agents protecteurs/pharmacologie , Agents protecteurs/composition chimique , Troubles de l'endormissement et du maintien du sommeil/traitement médicamenteux , Troubles de l'endormissement et du maintien du sommeil/métabolisme , Troubles de l'endormissement et du maintien du sommeil/physiopathologie , Troubles de l'endormissement et du maintien du sommeil/prévention et contrôle , Stress psychologique
5.
J Agric Food Chem ; 72(19): 10923-10935, 2024 May 15.
Article de Anglais | MEDLINE | ID: mdl-38691832

RÉSUMÉ

This study aimed to explore the ameliorative effects and potential mechanisms of Huangshan Umbilicaria esculenta polysaccharide (UEP) in dextran sulfate sodium-induced acute ulcerative colitis (UC) and UC secondary liver injury (SLI). Results showed that UEP could ameliorate both colon and liver pathologic injuries, upregulate mouse intestinal tight junction proteins (TJs) and MUC2 expression, and reduce LPS exposure, thereby attenuating the effects of the gut-liver axis. Importantly, UEP significantly downregulated the secretion levels of TNF-α, IL-1ß, and IL-6 through inhibition of the NF-κB pathway and activated the Nrf2 signaling pathway to increase the expression levels of SOD and GSH-Px. In vitro, UEP inhibited the LPS-induced phosphorylation of NF-κB P65 and promoted nuclear translocation of Nrf2 in RAW264.7 cells. These results revealed that UEP ameliorated UC and SLI through NF-κB and Nrf2-mediated inflammation and oxidative stress. The study first investigated the anticolitis effect of UEP, suggesting its potential for the treatment of colitis and colitis-associated liver disease.


Sujet(s)
Colite , Sulfate dextran , Facteur-2 apparenté à NF-E2 , Facteur de transcription NF-kappa B , Polyosides , Animaux , Souris , Polyosides/pharmacologie , Polyosides/composition chimique , Polyosides/administration et posologie , Sulfate dextran/effets indésirables , Mâle , Facteur-2 apparenté à NF-E2/métabolisme , Facteur-2 apparenté à NF-E2/génétique , Humains , Colite/traitement médicamenteux , Colite/induit chimiquement , Colite/métabolisme , Cellules RAW 264.7 , Facteur de transcription NF-kappa B/métabolisme , Facteur de transcription NF-kappa B/génétique , Souris de lignée C57BL , Agents protecteurs/pharmacologie , Agents protecteurs/administration et posologie , Agents protecteurs/composition chimique , Foie/effets des médicaments et des substances chimiques , Foie/métabolisme , Facteur de nécrose tumorale alpha/génétique , Facteur de nécrose tumorale alpha/métabolisme , Facteur de nécrose tumorale alpha/immunologie , Stress oxydatif/effets des médicaments et des substances chimiques , Interleukine-1 bêta/génétique , Interleukine-1 bêta/métabolisme , Interleukine-1 bêta/immunologie , Interleukine-6/génétique , Interleukine-6/métabolisme , Interleukine-6/immunologie , Rectocolite hémorragique/traitement médicamenteux , Rectocolite hémorragique/métabolisme , Rectocolite hémorragique/induit chimiquement , Lésions hépatiques dues aux substances/traitement médicamenteux , Lésions hépatiques dues aux substances/métabolisme , Mucine-2/génétique , Mucine-2/métabolisme
6.
J Agric Food Chem ; 72(26): 14630-14639, 2024 Jul 03.
Article de Anglais | MEDLINE | ID: mdl-38634619

RÉSUMÉ

Theaflavin-3,3'-digallate (TFDG) in black tea has a strong antioxidant capacity. However, its effect on diabetic liver and kidney injury and the underlying mechanisms remain unclear. In the present study, our findings indicated that TFDG administration effectively lowers the fasting blood glucose and serum lipid concentrations and enhances the functionality and cellular architecture of the liver and kidney in rats with diabetes. The data also showed that TFDG mitigates oxidative harm in the liver and kidney of rats afflicted with diabetes. Additionally, metformin combined with TFDG was significantly more effective in reducing blood glucose and oxidative stress. Further studies suggested that TFDG upregulates the Nrf2 signal pathway and circ-ITCH (hsa_circ_0001141) expression. Silencing of circ-ITCH by transfection of the interfering plasmid apparently reduces the effects of TFDG on the Nrf2 signal pathway and oxidative stress in high-glucose-treated hepatic and renal cells. In conclusion, the present study highlights the great potential of TFDG in ameliorating diabetic liver and kidney injury by up-regulating circ-ITCH to promote the Nrf2 signal pathway and provides a potential option for the prevention and treatment of diabetic complications.


Sujet(s)
Biflavonoïdes , Catéchine , Rein , Foie , Facteur-2 apparenté à NF-E2 , Stress oxydatif , Transduction du signal , Régulation positive , Animaux , Facteur-2 apparenté à NF-E2/métabolisme , Facteur-2 apparenté à NF-E2/génétique , Rats , Biflavonoïdes/pharmacologie , Catéchine/analogues et dérivés , Catéchine/administration et posologie , Catéchine/pharmacologie , Mâle , Foie/métabolisme , Foie/effets des médicaments et des substances chimiques , Transduction du signal/effets des médicaments et des substances chimiques , Rein/métabolisme , Rein/effets des médicaments et des substances chimiques , Humains , Stress oxydatif/effets des médicaments et des substances chimiques , Régulation positive/effets des médicaments et des substances chimiques , Rat Sprague-Dawley , Agents protecteurs/administration et posologie , Agents protecteurs/pharmacologie , Glycémie/métabolisme , Camellia sinensis/composition chimique , Diabète expérimental/métabolisme , Diabète expérimental/génétique , Diabète expérimental/traitement médicamenteux
7.
Inflammopharmacology ; 32(3): 2007-2022, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38573363

RÉSUMÉ

BACKGROUND: Dextran Sulfate Sodium (DSS) induces ulcerative colitis (UC), a type of inflammatory bowel disease (IBD) that leads to inflammation, swelling, and ulcers in the large intestine. The aim of this experimental study is to examine how sinomenine, a plant-derived alkaloid, can prevent or reduce the damage caused by DSS in the colon and rectum of rats. MATERIAL AND METHODS: Induction of ulcerative colitis (UC) in rats was achieved by orally administering a 2% Dextran Sulfate Sodium (DSS) solution, while the rats concurrently received oral administrations of sinomenine and sulfasalazine. The food, water intake was estimated. The body weight, disease activity index (DAI), colon length and spleen index estimated. Antioxidant, cytokines, inflammatory parameters and mRNA expression were estimated. The composition of gut microbiota was analyzed at both the phylum and genus levels in the fecal samples obtained from all groups of rats. RESULTS: Sinomenine treatment enhanced the body weight, colon length and reduced the DAI, spleen index. Sinomenine treatment remarkably suppressed the level of NO, MPO, ICAM-1, and VCAM-1 along with alteration of antioxidant parameters such as SOD, CAT, GPx, GR and MDA. Sinomenine treatment also decreased the cytokines like TNF-α, IL-1, IL-1ß, IL-6, IL-10, IL-17, IL-18 in the serum and colon tissue; inflammatory parameters viz., PAF, COX-2, PGE2, iNOS, NF-κB; matrix metalloproteinases level such as MMP-1 and MMP-2. Sinomenine significantly (P < 0.001) enhanced the level of HO-1 and Nrf2. Sinomenine altered the mRNA expression of RIP1, RIP3, DRP3, NLRP3, IL-1ß, caspase-1 and IL-18. Sinomenine remarkably altered the relative abundance of gut microbiota like firmicutes, Bacteroidetes, F/B ratio, Verrucomicrobia, and Actinobacteria. CONCLUSION: The results clearly indicate that sinomenine demonstrated a protective effect against DSS-induced inflammation, potentially through the modulation of inflammatory pathways and gut microbiota.


Sujet(s)
Rectocolite hémorragique , Sulfate dextran , Morphinanes , Facteur-2 apparenté à NF-E2 , Animaux , Morphinanes/pharmacologie , Rectocolite hémorragique/traitement médicamenteux , Rectocolite hémorragique/induit chimiquement , Rectocolite hémorragique/métabolisme , Rats , Facteur-2 apparenté à NF-E2/métabolisme , Mâle , Inflammation/traitement médicamenteux , Inflammation/métabolisme , Microbiome gastro-intestinal/effets des médicaments et des substances chimiques , Antioxydants/pharmacologie , Heme oxygenase (decyclizing)/métabolisme , Cytokines/métabolisme , Transduction du signal/effets des médicaments et des substances chimiques , Agents protecteurs/pharmacologie , Agents protecteurs/administration et posologie , Rat Wistar , Anti-inflammatoires/pharmacologie , Côlon/effets des médicaments et des substances chimiques , Côlon/métabolisme , Côlon/anatomopathologie
8.
Food Chem ; 451: 139337, 2024 Sep 01.
Article de Anglais | MEDLINE | ID: mdl-38663243

RÉSUMÉ

Alcoholic liver disease (ALD) is a serious health threat. Soybean meal peptide (SMP) supplementation may protect against this damage; however, the potential mechanism underlying the specific sequence of SMPs is unclear. Protein-protein interaction and proteomic analyses are effective methods for studying functional ingredients in diseases. This study aimed to investigate the potential mechanism of action of the peptide Gly-Thr-Tyr-Trp (GTYW) on ALD using protein-protein interaction and proteomic analyses. These results demonstrate that GTYW influenced the targets of glutathione metabolism (glutathione-disulfide reductase, glutathione S-transferase pi 1, and glutathione S-transferase mu 2). It also regulated the expression of targets related to energy metabolism and amino acid conversion (trypsin-2, cysteine dioxygenase type-1, and F6SJM7). Amino acid and lipid metabolisms were identified based on Gene Ontology annotation. These results indicate that GTYW might affect alcohol-related liver disease signaling pathways. This study provides evidence of the protective and nutritional benefits of SMPs in ALD treatment.


Sujet(s)
Glycine max , Maladies alcooliques du foie , Peptides , Protéomique , Animaux , Souris , Glycine max/composition chimique , Glycine max/métabolisme , Maladies alcooliques du foie/métabolisme , Maladies alcooliques du foie/prévention et contrôle , Maladies alcooliques du foie/génétique , Mâle , Peptides/composition chimique , Peptides/pharmacologie , Peptides/métabolisme , Peptides/administration et posologie , Humains , Souris de lignée C57BL , Agents protecteurs/pharmacologie , Agents protecteurs/administration et posologie , Agents protecteurs/composition chimique , Foie/métabolisme
9.
Pharm Dev Technol ; 29(4): 371-382, 2024 Apr.
Article de Anglais | MEDLINE | ID: mdl-38613468

RÉSUMÉ

Baicalin (BG), a natural product, has been used in the prevention and treatment of drug-induced liver injury (DILI); however, its poor solubility and extensive liver metabolism limit its pharmacological use. The aim of the present study was the formulation of fast-dissolving freeze-dried sublingual tablets (FFSTs) to increase BG dissolution, avoid first-pass metabolism, and overcome swallowing difficulties. FFSTs were prepared following a 23 factorial design. The effect of three independent variables namely matrix former, Maltodextrin, concentration (4%, and 6%), binder concentration (2%, and 3%), and binder type (Methocel E5, and Methocel E15) on the FFSTs' in-vitro disintegration time and percentage dissolution was studied along with other tablet characteristics. Differential scanning calorimetry, scanning electron microscopy, in-vitro HepG2 cell viability assay, and in-vivo characterization were also performed. F8 (6% Maltodextrin, 2% Mannitol, 2% Methocel E5), with desirability of 0.852, has been furtherly enhanced using 1%PEG (F10). F10 has achieved an in-vitro disintegration time of 41 secs, and 60.83% in-vitro dissolution after 2 min. Cell viability assay, in-vivo study in rats, and histopathological studies confirmed that pretreatment with F10 has achieved a significant hepatoprotective effect against acetaminophen-induced hepatotoxicity. The outcome of this study demonstrated that FFSTs may present a patient-friendly dosage form against DILI.


Sujet(s)
Survie cellulaire , Lésions hépatiques dues aux substances , Flavonoïdes , Lyophilisation , Solubilité , Comprimés , Animaux , Flavonoïdes/administration et posologie , Flavonoïdes/pharmacologie , Flavonoïdes/composition chimique , Survie cellulaire/effets des médicaments et des substances chimiques , Humains , Rats , Cellules HepG2 , Lyophilisation/méthodes , Mâle , Administration par voie sublinguale , Lésions hépatiques dues aux substances/prévention et contrôle , Lésions hépatiques dues aux substances/traitement médicamenteux , Agents protecteurs/pharmacologie , Agents protecteurs/administration et posologie , Foie/effets des médicaments et des substances chimiques , Foie/métabolisme , Rat Wistar
10.
J Sci Food Agric ; 104(10): 6085-6099, 2024 Aug 15.
Article de Anglais | MEDLINE | ID: mdl-38445528

RÉSUMÉ

BACKGROUND: Red Panax notoginseng (RPN) is one of the major processed products of P. notoginseng (PN), with more effective biological activities. However, the traditional processing method of RPN has some disadvantages, such as low conversion rate of ginsenosides and long processing time. RESULTS: In this work, we developed a green, safe, and efficient approach for RPN processing by aspartic acid impregnation pretreatment. Our results showed that the optimized temperature, steaming time, and concentration of aspartic acid were 120 °C, 1 h, and 3% respectively. The original ginsenosides in PN treated by aspartic acid (Asp-PN) were completely converted to rare saponins at 120 °C within just 1 h. The concentration of the rare ginsenosides in Asp-PN was two times higher than that in untreated RPN. In addition, we examined the protective effect of RPN and Asp-PN on acetaminophen-induced liver injury in a mouse model. The results showed that Asp-PN has significantly more potent hepatoprotective action than the RPN. The hepatoprotection of Asp-PN in acetaminophen-induced hepatotoxicity may be due to its anti-oxidative stress, anti-apoptotic, and anti-inflammatory activities. CONCLUSION: These results indicated that aspartic acid impregnation pretreatment may provide an effective method to shorten the steaming time, improve the conversion rate of ginsenosides, and enhance hepatoprotective activity of RPN. © 2024 Society of Chemical Industry.


Sujet(s)
Acide aspartique , Lésions hépatiques dues aux substances , Ginsénosides , Foie , Panax notoginseng , Agents protecteurs , Animaux , Panax notoginseng/composition chimique , Souris , Acide aspartique/composition chimique , Ginsénosides/composition chimique , Ginsénosides/pharmacologie , Mâle , Foie/effets des médicaments et des substances chimiques , Lésions hépatiques dues aux substances/prévention et contrôle , Lésions hépatiques dues aux substances/traitement médicamenteux , Agents protecteurs/pharmacologie , Agents protecteurs/composition chimique , Agents protecteurs/administration et posologie , Humains , Stress oxydatif/effets des médicaments et des substances chimiques , Médicaments issus de plantes chinoises/composition chimique , Médicaments issus de plantes chinoises/pharmacologie , Médicaments issus de plantes chinoises/administration et posologie , Saponines/composition chimique , Saponines/pharmacologie , Acétaminophène
11.
Int. j. morphol ; 41(5): 1527-1536, oct. 2023. ilus
Article de Anglais | LILACS | ID: biblio-1521022

RÉSUMÉ

SUMMARY: The 12C6+ heavy ion beam irradiation can cause bystander effects. The inflammatory cytokines, endocrine hormones and apoptotic proteins may be involved in 12C6+ irradiation-induced bystander effects. This study characterized the protective effects and mechanisms of Huangqi decoction (HQD) against 12C6+ radiation induced bystander effects. Wistar rats were randomly divided into control, 12C6+ heavy ion irradiation model, and high-dose/medium-dose/low-dose HQD groups. HE staining assessed the pathological changes of brain and kidney. Peripheral blood chemical indicators as well as inflammatory factors and endocrine hormones were detected. Apoptosis was measured with TUNEL. Proliferating cell nuclear antigen (PCNA) expression was determined with real-time PCR and Western blot.Irradiation induced pathological damage to the brain and kidney tissues. After irradiation, the numbers of white blood cells (WBC) and monocyte, and the expression of interleukin (IL)-2, corticotropin-releasing hormone (CRH) and PCNA decreased. The damage was accompanied by increased expression of IL-1β, IL-6, corticosterone (CORT) and adrenocorticotropic hormone (ACTH) as well as increased neuronal apoptosis. These effects were indicative of radiation-induced bystander effects. Administration of HQD attenuated the pathological damage to brain and kidney tissues, and increased the numbers of WBC, neutrophils, lymphocyte and monocytes, as well as the expression of IL-2, CRH and PCNA. It also decreased the expression of IL-1β, IL-6, CORT and ACTH as well as neuronal apoptosis. HQD exhibits protective effects against 12C6+ radiation-induced bystander effects. The underlying mechanism may involve the promotion of the production of peripheral blood cells, inhibition of inflammatory factors and apoptosis, and regulation of endocrine hormones.


La irradiación con haz de iones pesados 12C6+ puede provocar efectos secundarios. Las citoquinas inflamatorias, las hormonas endocrinas y las proteínas apoptóticas pueden estar involucradas en los efectos secundarios inducidos por la irradiación 12C6+. Este estudio caracterizó los efectos y mecanismos protectores de la decocción de Huangqi (HQD) contra los efectos externos inducidos por la radiación 12C6+. Las ratas Wistar se dividieron aleatoriamente en grupos control, modelo de irradiación de iones pesados 12C6+ y grupos de dosis alta/media/baja de HQD. La tinción con HE evaluó los cambios patológicos del cerebro y el riñón. Se detectaron indicadores químicos de sangre periférica, así como factores inflamatorios y hormonas endocrinas. La apoptosis se midió con TUNEL. La expresión del antígeno nuclear de células en proliferación (PCNA) se determinó mediante PCR en tiempo real y transferencia Western blot. La irradiación indujo daños patológicos en los tejidos cerebrales y renales. Después de la irradiación, disminuyó el número de glóbulos blancos (WBC) y monocitos, y la expresión de interleucina (IL)-2, hormona liberadora de corticotropina (CRH) y PCNA. El daño estuvo acompañado por una mayor expresión de IL-1β, IL-6, corticosterona (CORT) y hormona adrenocorticotrópica (ACTH), así como un aumento de la apoptosis neuronal. Estas alteraciones fueron indicativas de efectos inducidos por la radiación. La administración de HQD atenuó el daño patológico a los tejidos cerebrales y renales, y aumentó el número de leucocitos y monocitos, así como la expresión de IL-2, CRH y PCNA. También disminuyó la expresión de IL-1β, IL-6, CORT y ACTH, así como la apoptosis neuronal. HQD exhibe mecanismos protectores contra los efectos externos inducidos por la radiación 12C6+. El mecanismo subyacente puede implicar la promoción de la producción de células sanguíneas periféricas, la inhibición de factores inflamatorios y la apoptosis y la regulación de hormonas endocrinas.


Sujet(s)
Animaux , Femelle , Rats , Médicaments issus de plantes chinoises , Agents protecteurs/administration et posologie , Ions lourds/effets indésirables , Scutellaria baicalensis/composition chimique , Encéphale/effets des médicaments et des substances chimiques , Encéphale/effets des radiations , Corticolibérine , Test ELISA , Rat Wistar , Apoptose/effets des médicaments et des substances chimiques , Apoptose/effets des radiations , Hormone corticotrope , Antigène nucléaire de prolifération cellulaire , Système endocrine/effets des médicaments et des substances chimiques , Système endocrine/effets des radiations , Facteurs immunologiques/antagonistes et inhibiteurs , Rein/effets des médicaments et des substances chimiques , Rein/effets des radiations
12.
Int. j. morphol ; 41(2): 368-373, abr. 2023. ilus, tab
Article de Anglais | LILACS | ID: biblio-1440329

RÉSUMÉ

SUMMARY: To investigate if the administration of boric acid (BA) would exert any protective effect against possible nephrotoxicity and hepatotoxicity induced by the exposure to acrylamide (ACR) in rats. In our study, we used a total of 28 rats that were divided into four equal groups. Group 1: the control group which was not treated with any procedure. Group 2: the ACR group that was administered ACR 50 mg/kg/day via intraperitoneal (i.p) route for 14 days. Group 3: the BA group that was administered BA 200 mg/kg/ day via gavage via peroral (p.o) route for 14 days. Group 4: the ACR+BA group that was administered BA simultaneously with ACR. Total antioxidant and oxidant (TAS/TOS) capacities were measured in all groups at the end of the experiment. In addition, the specimens obtained were evaluated with histopathological examination. Studies showed that the ACR and ACr+BA groups were not significantly different in terms of hepatic TAS level while the TOS level was higher in the ACR group than the ACR+BA group. The groups did not show any significant difference regarding renal TAS and TOS levels. In the histopathological examination of the hepatic tissue, the histopathological injury score of the ACR group was significantly higher than those of the other groups whereas it was significantly lower in the ACR+BA group than the ACR group. Our study concluded that Boric acid had a protective effect against acrylamide- induced hepatotoxicity, but not against nephrotoxicity.


El objetivo de este estudio fue investigar si la administración de ácido bórico (BA) ejercería algún efecto protector frente a la posible nefrotoxicidad y hepatotoxicidad inducida por la exposición a acrilamida (ACR) en ratas. En nuestro estudio, utilizamos un total de 28 ratas que se dividieron en cuatro grupos iguales. Grupo 1: grupo control que no fue tratado. Grupo 2: grupo ACR al que se le administró ACR 50 mg/kg/día por vía intraperitoneal (i.p) durante 14 días. Grupo 3: grupo BA al que se le administró BA 200 mg/kg/día por sonda por vía peroral (p.o) durante 14 días. Grupo 4: grupo ACR+BA al que se administró BA simultáneamente con ACR. Las capacidades antioxidantes y oxidantes totales (TAS/TOS) se midieron en todos los grupos al final del experimento. Además, los especímenes obtenidos fueron evaluados con examen histopatológico. Los estudios demostraron que los grupos ACR y ACr+BA no fueron significativamente diferentes en términos del nivel hepático de TAS, mientras que el nivel de TOS fue mayor en el grupo ACR que en el grupo ACR+BA. Los grupos no mostraron ninguna diferencia significativa con respecto a los niveles renales de TAS y TOS. En el examen histopatológico del tejido hepático, la puntuación de lesión histopatológica del grupo ACR fue significativamente mayor que la de los otros grupos, mientras que fue significativamente menor en el grupo ACR+BA que en el grupo ACR. Nuestro estudio concluyó que el ácido bórico tiene un efecto protector contra la hepatotoxicidad inducida por acrilamida, pero no contra la nefrotoxicidad.


Sujet(s)
Animaux , Rats , Acides boriques/administration et posologie , Acrylamide/toxicité , Lésions hépatiques dues aux substances/prévention et contrôle , Atteinte rénale aigüe/prévention et contrôle , Biochimie , Agents protecteurs/administration et posologie , Lésions hépatiques dues aux substances/anatomopathologie , Atteinte rénale aigüe/induit chimiquement , Atteinte rénale aigüe/anatomopathologie , Rein/effets des médicaments et des substances chimiques , Rein/physiopathologie , Foie/effets des médicaments et des substances chimiques , Foie/physiopathologie
13.
Ren Fail ; 45(1): 2194434, 2023 Dec.
Article de Anglais | MEDLINE | ID: mdl-36974638

RÉSUMÉ

BACKGROUND: Patients with diabetic kidney disease (DKD) are at increased risk to develop post-contrast acute kidney injury (AKI). Diabetic patients under dipeptidyl peptidase 4 inhibitors (DPP4Is) experience a lower propensity to develop AKI. We speculated that linagliptin as a single agent or in combination with allopurinol may reduce the incidence of post-contrast AKI in stage 3-5 chronic kidney disease (CKD) patients with underlying DKD. METHODS: Out of 951 DKD patients eligible for this study, 800 accepted to sign informed consent. They were randomly allocated to 4 equal groups that received their prophylaxis for 2 days before and after radiocontrast. The first control group received N-acetyl cysteine and saline, the 2nd received allopurinol, the 3rd group received linagliptin, and the 4th received both allopurinol and linagliptin. Post-procedure follow-up for kidney functions was conducted for 2 weeks in all patients. RESULTS: 20, 19, 14, and 8 patients developed post-contrast AKI in groups 1 through 4, respectively. Neither linagliptin nor allopurinol was superior to N-acetyl cysteine and saline alone. However, the combination of the two agents provided statistically significant renal protection: post-contrast AKI in group 4 was significantly lower than in groups 1 and 2 (p < 0.02 and <0.03, respectively). None of the post-contrast AKI cases required dialysis. CONCLUSION: Linagliptin and allopurinol in combination may offer protection against post-contrast AKI in DKD exposed to radiocontrast. Further studies are needed to support this view. TRIAL REGISTRATION CLINICALTRIALS.GOV: NCT03470454.


Sujet(s)
Atteinte rénale aigüe , Allopurinol , Produits de contraste , Néphropathies diabétiques , Linagliptine , Agents protecteurs , Humains , Atteinte rénale aigüe/induit chimiquement , Atteinte rénale aigüe/étiologie , Atteinte rénale aigüe/prévention et contrôle , Allopurinol/administration et posologie , Allopurinol/usage thérapeutique , Néphropathies diabétiques/classification , Néphropathies diabétiques/complications , Néphropathies diabétiques/diagnostic , Défaillance rénale chronique/complications , Défaillance rénale chronique/diagnostic , Linagliptine/administration et posologie , Linagliptine/usage thérapeutique , Études prospectives , Insuffisance rénale chronique/classification , Insuffisance rénale chronique/complications , Insuffisance rénale chronique/diagnostic , Produits de contraste/effets indésirables , Chimioprévention/méthodes , Association de médicaments , Acétylcystéine/administration et posologie , Acétylcystéine/usage thérapeutique , Agents protecteurs/administration et posologie , Agents protecteurs/effets indésirables , Agents protecteurs/usage thérapeutique , Solution physiologique salée/administration et posologie , Solution physiologique salée/usage thérapeutique
14.
Hum Exp Toxicol ; 41: 9603271221076107, 2022.
Article de Anglais | MEDLINE | ID: mdl-35264022

RÉSUMÉ

Diabetic retinopathy (DR) is a common diabetic complication that severely impacts the life quality of diabetic patients. Recently, cellular senescence in human retinal endothelial cells (HRECs) induced by high glucose has been linked to the pathogenesis of DR. Fluorometholone (FML) is a glucocorticoid drug applied in the treatment of inflammatory and allergic disorders of the eye. The objective of the present study is to investigate the protective function of FML on high glucose-induced cellular senescence in HRECs. The in vitro injury model was established by stimulating HRECs with 30 mm glucose. After evaluating the cytotoxicity of FML in HRECs, 0.05% and 0.1% FML were used as the optimal concentration in the entire experiment. It was found that the excessive released inflammatory factors including tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-8 (IL-8) in HRECs induced by high glucose were significantly suppressed by FML, accompanied by the inhibitory effects on the expression levels of vascular endothelial growth factor (VEGF) and tissue factor (TF). Declined telomerase activity and enhanced senescence-associated ß-galactosidase (SA-ß-gal) activity were found in high glucose-challenged HRECs, which were dramatically alleviated by FML, accompanied by the inactivation of the p53/p21 and retinoblastoma (Rb) signaling. Interestingly, FML ameliorated high glucose-induced dephosphorylation of Akt. Lastly, the protective effects of FML against high glucose-induced cellular senescence in HRECs were abolished by the co-treatment of the PI3K/Akt signaling inhibitor LY294002, suggesting the involvement of this pathway. Taken together, these data revealed that FML-inhibited high glucose-induced cellular senescence mediated by Akt in HERCs, suggesting a novel molecular mechanism of FML.


Sujet(s)
Prolifération cellulaire/effets des médicaments et des substances chimiques , Vieillissement de la cellule/effets des médicaments et des substances chimiques , Rétinopathie diabétique/prévention et contrôle , Cellules endothéliales/effets des médicaments et des substances chimiques , Fluorométholone/pharmacologie , Agents protecteurs/pharmacologie , Rétine/effets des médicaments et des substances chimiques , Animaux , Cellules cultivées/effets des médicaments et des substances chimiques , Diabète expérimental , Rétinopathie diabétique/physiopathologie , Fluorométholone/administration et posologie , Humains , Agents protecteurs/administration et posologie
15.
Oxid Med Cell Longev ; 2022: 1792894, 2022.
Article de Anglais | MEDLINE | ID: mdl-35251467

RÉSUMÉ

Excessive reactive oxygen species (ROS) contribute to damage of retinal cells and the development of retinal diseases including age-related macular degeneration (AMD). ROS result in increased metabolites of lipoxygenases (LOXs), which react with ROS to induce lipid peroxidation and may lead to ferroptosis. In this study, the effect of 5-LOX inhibition on alleviating ROS-induced cell death was evaluated using sodium iodate (NaIO3) in the retinal pigment epithelium (RPE) cell line ARPE-19 and a mouse model investigating oxidative stress in AMD. We demonstrated that NaIO3 induced cell death in the RPE cells through mechanisms including ferroptosis. Inhibition of 5-LOX with specific inhibitor, Zileuton, or siRNA knockdown of ALXO5 mitigated NaIO3-induced lipid peroxidation, mitochondrial damage, DNA impairment, and cell death in ARPE-19 cells. Additionally, in the mouse model, pretreatment with Zileuton reduced the NaIO3-induced lipid peroxidation of RPE cells, cell death in the photoreceptor layer of the retina, inflammatory responses, and degeneration of both the neuroretina and RPE monolayer cells. Our results suggest that 5-LOX plays a crucial role in ROS-induced cell death in the RPE and that regulating 5-LOX activity could be a useful approach to control ROS and ferroptosis-induced damage, which promote degeneration in retinal diseases.


Sujet(s)
Arachidonate 5-lipoxygenase/métabolisme , Ferroptose/effets des médicaments et des substances chimiques , Ferroptose/génétique , Iodates/effets indésirables , Dégénérescence maculaire/induit chimiquement , Dégénérescence maculaire/métabolisme , Épithélium pigmentaire de la rétine/métabolisme , Transduction du signal/effets des médicaments et des substances chimiques , Transduction du signal/génétique , Animaux , Arachidonate 5-lipoxygenase/génétique , Lignée cellulaire , Modèles animaux de maladie humaine , Techniques de knock-down de gènes/méthodes , Humains , Hydroxy-urée/administration et posologie , Hydroxy-urée/analogues et dérivés , Inhibiteurs de la lipoxygénase/administration et posologie , Mâle , Souris , Souris de lignée C57BL , Stress oxydatif/effets des médicaments et des substances chimiques , Stress oxydatif/génétique , Agents protecteurs/administration et posologie , Espèces réactives de l'oxygène/métabolisme , Épithélium pigmentaire de la rétine/effets des médicaments et des substances chimiques , Transfection/méthodes
16.
Toxins (Basel) ; 14(2)2022 02 11.
Article de Anglais | MEDLINE | ID: mdl-35202162

RÉSUMÉ

Clostridium botulinum produces botulinum neurotoxin (BoNT), which is the most toxic known protein and the causative agent of human botulism. BoNTs have similar structures and functions, comprising three functional domains: catalytic domain (L), translocation domain (HN), and receptor-binding domain (Hc). In the present study, BoNT/E was selected as a model toxin to further explore the immunological significance of each domain. The EL-HN fragment (L and HN domains of BoNT/E) retained the enzymatic activity without in vivo neurotoxicity. Extensive investigations showed EL-HN functional fragment had the highest protective efficacy and contained some functional neutralizing epitopes. Further experiments demonstrated the EL-HN provided a superior protective effect compared with the EHc or EHc and EL-HN combination. Thus, the EL-HN played an important role in immune protection against BoNT/E and could provide an excellent platform for the design of botulinum vaccines and neutralizing antibodies. The EL-HN has the potential to replace EHc or toxoid as the optimal immunogen for the botulinum vaccine.


Sujet(s)
Anticorps neutralisants/immunologie , Vaccins antibactériens/administration et posologie , Vaccins antibactériens/immunologie , Botulisme/immunologie , Botulisme/prévention et contrôle , Clostridium botulinum/immunologie , Neurotoxines/toxicité , Animaux , Clostridium botulinum/effets des médicaments et des substances chimiques , Modèles animaux de maladie humaine , Femelle , Humains , Souris , Agents protecteurs/administration et posologie , Sérogroupe
17.
Asian Pac J Cancer Prev ; 23(2): 703-713, 2022 Feb 01.
Article de Anglais | MEDLINE | ID: mdl-35225484

RÉSUMÉ

BACKGROUND: The sea cucumber, Bohadschia marmorata, is a marine echinoderm consumed and used as a medication. Extract of this species displays a broad spectrum of bioactivity, such as antifungal, antibacterial, immunomodulatory, and cytotoxic properties. This investigation explored sea cucumber extract for hepatorenal protection against the toxicity of methotrexate (MTX). METHODS: Four groups of mice were divided into G1: control, G2: MTX treated, G3: B. marmorata extract-treated daily for 14 days, and G4: B. marmorata extract and MTX treated. RESULTS AND CONCLUSIONS: Biochemical analysis and histopathological examination of liver tissue showed that administration of MTX increased serum levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT), lowered levels of serum albumin, total protein, Superoxide dismutase (SOD), catalase (CAT), and glutathione (GSH). Administration of B. marmorata extract to MTX- injected mice significantly reversed the increase in serum levels of liver enzymes and induced a significant elevation in serum albumin and total protein levels. SOD, CAT, and GSH levels returned to nearly normal levels. Histopathological examination indicated fewer signs of toxicity in liver and kidney tissues of mice treated with both extract and MTX compared to MTX treatment alone. An extract of B. marmorata will protect mice from hepatorenal toxicity induced by MTX.


Sujet(s)
Antinéoplasiques/effets indésirables , Lésions hépatiques dues aux substances/prévention et contrôle , Méthotrexate/effets indésirables , Agents protecteurs/administration et posologie , Concombres de mer/composition chimique , Alanine transaminase/sang , Animaux , Aspartate aminotransferases/sang , Lésions hépatiques dues aux substances/étiologie , Glutathion/sang , Foie/métabolisme , Mâle , Souris , Sérumalbumine/métabolisme , Superoxide dismutase/sang
18.
Comput Math Methods Med ; 2022: 9275406, 2022.
Article de Anglais | MEDLINE | ID: mdl-35211189

RÉSUMÉ

BACKGROUND: Renal dysfunction after kidney transplantation may be influenced by many reasons. This study was designed to evaluate whether the administration of dexmedetomidine (Dex) could ameliorate renal function and prognosis after kidney transplantation. METHODS: A total of 65 patients were divided into Dex group (n = 33) and Con group (Con, n = 32). Dex group intravenously received an initial loading dose of 0.6 µg/kg Dex for 15 min before anaesthesia induction, followed by a rate of 0.4 µg/kg/h until 30 min after kidney reperfusion. By contrast, Con group received saline. The concentration of urinary kidney injury molecule-1 (KIM-1), serum creatinine (Cr), blood urea, urine output, ß2 microglobulin (ß2-MG), Cystatin C (CysC), and estimated glomerular filtration rate (eGFR) was recorded and compared between two groups during the course of the hospitalization or follow-up. Mean arterial pressure (MAP) and heart rate (HR), vasoactive drugs, and anaesthetics were recorded during the operation. Pain degree was evaluated using a visual analogue scale (VAS) after operation. Delayed graft function (DGF), graft loss, length of hospital stay, and mortality were compared between groups. RESULTS: The concentration of KIM-1 in Dex group was lower than Con group at 2 h (P = 0.018), 24 h (P = 0.013), 48 h (P < 0.01), and 72 h (P < 0.01) after reperfusion. MAP of Dex group after tracheal intubation (P = 0.012) and incision (P = 0.018) and HR after intubation (P = 0.021) were lower than that of Con group. The dosage of sufentanil during operation in Dex group was less than Con group (P = 0.039). Patients that used atropine in Dex group were more than Con group (P = 0.027). Patients who received Dex presented with lower VAS scores at 6 h (P = 0.01) and 12 h (P = 0.002) after operation. Concentration of serum Cr and blood urea had no significant differences between groups before operation and on postoperative day 1 to 6. Urine output was recorded for 6 days after operation and had no differences between groups. Also, no differences were identified between two groups in urea, Cr, ß2-MG, CysC, and eGFR in the first 3 months after operation. Incidence of DGF after operation was detected no difference between groups, while length of hospital stay in Dex group was less than Con group (P = 0.012). CONCLUSION: Dex can decrease kidney injury marker level, attenuate perioperative stress, relieve the dosage of sufentanil and postoperative pain, and reduce length of hospital stay. However, Dex is not associated with changes in prognosis in the first 3 months after transplantation.


Sujet(s)
Dexmédétomidine/administration et posologie , Transplantation rénale/méthodes , Atteinte rénale aigüe/étiologie , Atteinte rénale aigüe/physiopathologie , Atteinte rénale aigüe/prévention et contrôle , Agonistes des récepteurs alpha-2 adrénergiques/administration et posologie , Adulte , Marqueurs biologiques/sang , Marqueurs biologiques/urine , Biologie informatique , Femelle , Humains , Période peropératoire , Défaillance rénale chronique/physiopathologie , Défaillance rénale chronique/chirurgie , Tests de la fonction rénale , Transplantation rénale/effets indésirables , Mâle , Adulte d'âge moyen , Complications postopératoires/étiologie , Complications postopératoires/physiopathologie , Complications postopératoires/prévention et contrôle , Pronostic , Agents protecteurs/administration et posologie , Lésion d'ischémie-reperfusion/étiologie , Lésion d'ischémie-reperfusion/physiopathologie , Lésion d'ischémie-reperfusion/prévention et contrôle
19.
Oxid Med Cell Longev ; 2022: 3990607, 2022.
Article de Anglais | MEDLINE | ID: mdl-35126812

RÉSUMÉ

Neutrophils release chromatin and antimicrobial proteins to trap and kill microbes, which is termed as neutrophil extracellular trap (NET) formation. NETs play a pivotal role in host defense against infection. However, emerging evidence indicated that NETs also contribute to an exaggerated inflammatory response and organic injuries in sepsis. Zingerone, a natural compound extracted from Zingiber officinale, exerts antioxidant, anti-inflammatory, and antioncogenic properties. In this study, we found that treatment with zingerone reduced organ injury and improved the outcome in a cecal ligation puncture- (CLP-) induced polymicrobial sepsis model. Administration of zingerone also alleviates reactive oxygen species (ROS) accumulation and systematic inflammation in septic mice and inhibits neutrophil extracellular traps (NETs) formation in vivo and in vitro. Furthermore, inhibition of nuclear factor erythroid 2-related factor 2 (Nrf2) with its specific antagonist significantly counteracted the suppressive effects of zingerone on ROS and NETs and retarded the protective role of zingerone against sepsis-associated organ injury. In addition, exposure to zingerone does not affect phagocytic activity of neutrophils in vitro and bacterial dissemination in vivo. Above all, our results indicate that zingerone treatment obviously attenuates NET formation and inflammatory response via Nrf2-mediated ROS inhibition, thus providing a novel therapeutic strategy against sepsis-induced injury.


Sujet(s)
Pièges extracellulaires/métabolisme , Guaïacol/analogues et dérivés , Facteur-2 apparenté à NF-E2/métabolisme , Granulocytes neutrophiles/métabolisme , Agents protecteurs/administration et posologie , Espèces réactives de l'oxygène/métabolisme , Sepsie/traitement médicamenteux , Transduction du signal/effets des médicaments et des substances chimiques , Animaux , Donneurs de sang , Cellules cultivées , Cytokines/sang , Modèles animaux de maladie humaine , Pièges extracellulaires/effets des médicaments et des substances chimiques , Guaïacol/administration et posologie , Humains , Mâle , Souris , Souris de lignée C57BL , Granulocytes neutrophiles/effets des médicaments et des substances chimiques , Phagocytose/effets des médicaments et des substances chimiques , Sepsie/sang , Résultat thérapeutique
20.
Hum Exp Toxicol ; 41: 9603271211066065, 2022.
Article de Anglais | MEDLINE | ID: mdl-35130744

RÉSUMÉ

Cardiovascular disorders are the leading cause of death globally. Rosuvastatin is a member of statins (inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase) with many pleiotropic properties. This study investigated cardioprotective effects of rosuvastatin in isoprenaline-induced myocardial injury. Male rats were given rosuvastatin (1, 5, or 10 mg/kg, oral) daily for 1 week and on seventh and eighth day isoprenaline (150 mg/kg, subcutaneous) was given to induce cardiac injury. On ninth day, rats were euthanized and different samples were harvested for analysis. Isoprenaline administration resulted in increased cardiac mass, increased cardiac injury marker levels (cTnI, CK-MB, ALT, and AST), increased lipid/protein oxidation, and increased cardiac nitrite levels. It also decreased superoxide dismutase, CAT, GST, and glutathione reductase activities, and total antioxidant activity. Isoprenaline also increased TNF-α and IL-6 levels. Decreased mRNA expression of Nrf2 and Bcl-2 along with increased mRNA expression of Bax, eNOS and iNOS genes was observed in isoprenaline treated animals. Histopathological evaluations of rosuvastatin pre-treated groups showed reduction of myocardial necrosis. Pretreatment with rosuvastatin (5 and 10 mg/kg) reduced many of these pathological changes. The current study showed that rosuvastatin significantly reduces myocardial injury induced by isoprenaline.


Sujet(s)
Protéines adaptatrices de la transduction du signal/effets des médicaments et des substances chimiques , Régulation de l'expression des gènes/effets des médicaments et des substances chimiques , Isoprénaline/effets indésirables , Infarctus du myocarde/prévention et contrôle , Facteur-2 apparenté à NF-E2/effets des médicaments et des substances chimiques , Nitric oxide synthase type II/effets des médicaments et des substances chimiques , Protéines proto-oncogènes c-bcl-2/effets des médicaments et des substances chimiques , Rosuvastatine de calcium/administration et posologie , Protéines adaptatrices de la transduction du signal/génétique , Animaux , Antioxydants , Modèles animaux de maladie humaine , Relation dose-effet des médicaments , Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase/administration et posologie , Isoprénaline/usage thérapeutique , Mâle , Infarctus du myocarde/induit chimiquement , Infarctus du myocarde/traitement médicamenteux , Facteur-2 apparenté à NF-E2/génétique , Nitric oxide synthase type II/génétique , Agents protecteurs/administration et posologie , Protéines proto-oncogènes c-bcl-2/génétique , Rats , Rat Wistar
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...